Q2 and H1 saw strong organic growth in revenue, operating income, and EPS, driven by smoke-free products and robust combustible performance. Guidance remains unchanged as increased U.S. investment is planned for H2, especially behind ZYN and IQOS ILUMA.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.